UAE Ministry of Health & Prevention (MoHAP) has approved Xonrid® Gel

The UAE Ministry of Health & Prevention (MoHAP) has approved Xonrid® Gel, a topical gel for radiotherapy-induced dermatitis, already classified as a medical device in the EU, and has received 510(K) FDA clearance in the US.

Radiotherapy-induced dermatitis or Radiation dermatitis is a side effect of external beam ionizing radiation. It is also called radiodermatitis, x-ray dermatitis, radiation skin damage or a radiation burn. Most commonly, radiation-induced dermatitis is caused by radiotherapy for underlying malignancies.

Xonrid® Gel along with Gelclair®, is manufactured by Helsinn Healthcare SA, Switzerland.

Xonrid® Gel will soon be available at all UAE Hospitals & Cancer treatment centers.

Pharma Solutions is the exclusive partner of Helsinn Healthcare SA in the UAE serving all DHA & SEHA Hospitals.